clopidogrel

(redirected from antiplatelet therapy)
Also found in: Thesaurus, Medical, Encyclopedia.

clo·pid·o·grel

 (klō-pĭd′ə-grĕl′)
n.
A drug, C16H16ClNO2S, given in the form of its bisulfate, that inhibits platelet aggregation and is used in the treatment of patients with peripheral arterial disease, certain forms of angina, or a recent history of heart attack or stroke.

[c(h)lo(ro)- + p(yr)id(ine) + -grel, platelet aggregation inhibitor suffix (ultimately from aggregation).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Translations

clopidogrel

n clopidogrel m
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Translate-POPs [19] research randomly assigned ACS patients to a strategy of platelet function monitoring, with drug adjustment in patients who had poor responses to antiplatelet therapy, or to a conventional strategy without monitoring and drug adjustment.
His presentation was mainly based on the American College of Cardiology/American Heart Association 2016 Guidelines on dual antiplatelet therapy in ACS.
One contributing factor could be overmedication caused by a combination of warfarin and antiplatelet therapy. If you have AF and you're taking warfarin and antiplatelet medications, talk with your doctor about whether you could reduce your medication intake.
DUAL ANTIPLATELET THERAPY AFTER STENTING: LONGER IS IS BETTER.
The current guidelines suggest one year of dual antiplatelet therapy with aspirin and clopidogrel for drug eluting stents and one month for bare metal stents.
Aspirin is accepted as a standard antiplatelet therapy in patients with lacunar infarc ts.
Cardiologists, biophysicists, neurologists, and others from Europe and North America examine the impact of antiplatelet therapy in heart disease; the use of aspirin and ticagrelor, clopidogrel, prasugrel, dipyridamole, and voapaxar and atopaxar in acute coronary syndrome and atrial fibrillation, coronary artery disease, high-risk acute coronary syndrome, and antithrombotic treatment; genetic considerations; antiplatelet regimens administered during or following coronary stent implantation; bleeding risk; antiplatelet therapy in stroke prevention; and challenges in atrial fibrillation.
To assess the effect of antiplatelet therapy, the standard has become light transmission and whole blood aggregation, which have been incorporated into a newer generation of point-of-care platelet function analyzers.
Their results support the need for a randomized controlled study to investigate alternative antiplatelet therapy in patients with aspirin resistance.
(The study continues with a concurrent randomization that is comparing the efficacy of usual and "intensive" blood pressure control.) The antiplatelet randomization stopped because the results showed a "surprising," statistically significant increased rate of all-cause mortality and major hemorrhages in patients treated with dual antiplatelet therapy.
We look forward to seeing additional clinical support for the use of Genous in challenging cases, such as diabetic patients and those who cannot tolerate a year of dual antiplatelet therapy."